Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brigimadlin in advanced dedifferentiated liposarcoma
NCT05218499Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of brigimadlin in Liposarcoma, sponsored by Boehringer Ingelheim. Started Mar 2022; status: completed.
02
Drugs
brigimadlin
03
Conditions
Liposarcoma
Beyond the preview
Go deeper on NCT05218499.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05218499.